Wells Fargo’s Benitec Biopharma BNTC Stock Holding History

Wells Fargo’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Buy	17,942 +10,897	+155%	+$129K	﹤0.01%	5078
2026 Q1	$75K	Sell	7,045 -9,217	-57%	-$107K	﹤0.01%	5262
2025 Q4	$219K	Buy	16,262 +7,129	+78%	+$98.6K	﹤0.01%	5026
2025 Q3	$128K	Buy	9,133 +1,655	+22%	+$21.1K	﹤0.01%	5186
2025 Q2	$87.5K	Buy	+7,478	New	+$105K	﹤0.01%	5277
2024 Q2	–	Sell	-17	Closed	-$89	–	6943
2024 Q1	$89	Hold	17	–	–	﹤0.01%	6689
2023 Q4	$55	Buy	17 +4	+31%	+$13	﹤0.01%	6913
2023 Q3	$39	Buy	13 +1	+8%	+$3	﹤0.01%	6985
2023 Q2	$48	Buy	12 +1	+9%	+$4	﹤0.01%	7064
2023 Q1	$41	Hold	11	–	–	﹤0.01%	7162
2022 Q4	$32	Buy	11 +8	+267%	+$27	﹤0.01%	7142
2022 Q3	$0	Hold	3	–	–	﹤0.01%	6678
2022 Q2	$0	Hold	3	–	–	﹤0.01%	6816
2022 Q1	$0	Hold	3	–	–	﹤0.01%	7075
2021 Q4	$0	Buy	3 +1	+50%	+$56	﹤0.01%	7230
2021 Q3	$0	Sell	2 -1	-33%	-$66	﹤0.01%	6977
2021 Q2	$0	Buy	3 +1	+50%	+$78	﹤0.01%	6912
2021 Q1	$0	Hold	2	–	–	﹤0.01%	6896
2020 Q4	$0	Buy	+2	New	+$99	﹤0.01%	6495
2020 Q3	–	Hold	0	–	–	–	6342

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Wells Fargo's BNTC Position: Q2 2026 in Review

Wells Fargo increased its Benitec Biopharma (BNTC) stake by 155% in Q2 2026, buying an estimated $129K and bringing the position to 17,942 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #5078.

Wells Fargo first reported a position in BNTC in Q4 2020 and has held it in 19 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Wells Fargo held 17,942 shares of Benitec Biopharma worth $240K as of Q2 2026.
Wells Fargo bought 10,897 Benitec Biopharma shares in Q2 2026, an estimated $129K.
Benitec Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5078 holding.
Wells Fargo first reported a position in Benitec Biopharma in Q4 2020 and has held it in 19 quarters since.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.